HF-158K1 by HighField Biopharmaceuticals for Pancreatic Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.

In Montana, 911 calls reveal impact of heat waves on rural seniors

Missoula is one of Montana’s largest cities but is surrounded by rural mountain communities where cattle ranching is king.

September 12, 2024

E-cigarettes more effective for smoking cessation than conventional nicotine-replacement therapy

Nicotine e-cigarettes are more effective in helping people quit smoking than conventional nicotine-replacement therapy (NRT), according to the latest Cochrane review co-led by a University

January 8, 2024

Fibromyalgia patients may be at increased risk of death

Fibromyalgia, a condition that causes persistent widespread pain and fatigue, may be linked to a heightened risk of death as a result of vulnerability to

July 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.